Keros Therapeutics Inc logo


Keros Therapeutics Inc


Earnings Summary

Net Profits


Net Profits:

Keros Therapeutics Inc’s net profit fell -74.54% since last year same period to $-27.27Mn in the Q2 2022. On a quarterly growth basis, Keros Therapeutics Inc has generated -12.73% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Keros Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Keros Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.06 - a -23.26% fall from last quarter’s estimates.

EPS Estimate Current Year:

Keros Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.06.

Key Ratios

Key ratios of the Keros Therapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Keros Therapeutics Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Keros Therapeutics Inc’s return on equity (ROE) stands at -0.35.

Dividend Per Share (DPS):

Keros Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Keros Therapeutics Inc
Commercial Services